Literature DB >> 29377994

Basic mechanisms of vascularization in endometriosis and their clinical implications.

Matthias W Laschke1, Michael D Menger1.   

Abstract

BACKGROUND: Vascularization is a major hallmark in the pathogenesis of endometriosis. An increasing number of studies suggests that multiple mechanisms contribute to the vascularization of endometriotic lesions, including angiogenesis, vasculogenesis and inosculation. OBJECTIVE AND RATIONALE: In this review, we provide an overview of the basic mechanisms of vascularization in endometriosis and give special emphasis on their future clinical implications in the diagnosis and therapy of the disease. SEARCH
METHODS: Literature searches were performed in PubMed for English articles with the key words 'endometriosis', 'endometriotic lesions', 'angiogenesis', 'vascularization', 'vasculogenesis', 'endothelial progenitor cells' and 'inosculation'. The searches included both animal and human studies. No restriction was set for the publication date. OUTCOMES: The engraftment of endometriotic lesions is typically associated with angiogenesis, i.e. the formation of new blood vessels from pre-existing ones. This angiogenic process underlies the complex regulation by angiogenic growth factors and hormones, which activate intracellular pathways and associated signaling molecules. In addition, circulating endothelial progenitor cells (EPCs) are mobilized from the bone marrow and recruited into endometriotic lesions, where they are incorporated into the endothelium of newly developing microvessels, referred to as vasculogenesis. Finally, preformed microvessels in shed endometrial fragments inosculate with the surrounding host microvasculature, resulting in a rapid blood supply to the ectopic tissue. These vascularization modes offer different possibilities for the establishment of novel diagnostic and therapeutic approaches. Angiogenic growth factors and EPCs may serve as biomarkers for the diagnosis and classification of endometriosis. Blood vessel formation and mature microvessels in endometriotic lesions may be targeted by means of anti-angiogenic compounds and vascular-disrupting agents. WIDER IMPLICATIONS: The establishment of vascularization-based approaches in the management of endometriosis still represents a major challenge. For diagnostic purposes, reliable angiogenic and vasculogenic biomarker panels exhibiting a high sensitivity and specificity must be identified. For therapeutic purposes, novel compounds selectively targeting the vascularization of endometriotic lesions without inducing severe side effects are required. Recent progress in the field of endometriosis research indicates that these goals may be achieved in the near future.
© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  VEGF; angiogenesis; endometriosis; endothelial progenitor cells; estrogen; inosculation; miRNA; peritoneal fluid; vascularization; vasculogenesis

Year:  2018        PMID: 29377994     DOI: 10.1093/humupd/dmy001

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  27 in total

1.  Robotic single-site endometriosis resection using near-infrared fluorescence imaging with indocyanine green: a prospective case series and review of literature.

Authors:  Jayapriya Jayakumaran; Zoran Pavlovic; Daniele Fuhrich; Karen Wiercinski; Cynthia Buffington; Aileen Caceres
Journal:  J Robot Surg       Date:  2019-04-01

2.  APEX1/miR-24 axis: a promising therapeutic target in endometriosis.

Authors:  Aili Tan; Peng Ruan; Pengxing Sun
Journal:  Arch Gynecol Obstet       Date:  2021-01-27       Impact factor: 2.344

3.  Botulinum toxin for chronic pelvic pain in women with endometriosis: a cohort study of a pain-focused treatment.

Authors:  Hannah K Tandon; Pamela Stratton; Ninet Sinaii; Jay Shah; Barbara I Karp
Journal:  Reg Anesth Pain Med       Date:  2019-07-08       Impact factor: 6.288

4.  Exploring the Potential Key IncRNAs with Endometriosis by Construction of a ceRNA Network.

Authors:  Chenglei Gu; Yuanguang Meng; Qingqing Meng; Wensheng Fan; Mingxia Ye; Qian Zhang; Nina Zhang; Lian Li
Journal:  Int J Gen Med       Date:  2021-08-05

5.  Low-Nutrient Environment-Induced Changes in Inflammation, Cell Proliferation, and PGC-1α Expression in Stromal Cells with Ovarian Endometriosis.

Authors:  Koki Shimura; Yosuke Tarumi; Maya Fujii; Kanae Ogawa; Eiko Maeda; Yukiko Tanaka; Hiroyuki Okimura; Hisashi Kataoka; Osamu Takaoka; Fumitake Ito; Akemi Koshiba; Khaleque N Khan; Izumi Kusuki; Jo Kitawaki; Taisuke Mori
Journal:  Reprod Sci       Date:  2022-10-05       Impact factor: 2.924

Review 6.  Strategies for modelling endometrial diseases.

Authors:  Alina R Murphy; Hannes Campo; J Julie Kim
Journal:  Nat Rev Endocrinol       Date:  2022-09-01       Impact factor: 47.564

7.  Macrophages and Natural Killer Cells Characteristics in Variously Colored Endometriotic Lesions: A Cross-Sectional Analytic Study.

Authors:  Areepan Sophonsritsuk; Nipawan Attawattanakul; Morakot Sroyraya; Sineenart Songkoomkrong; Wanwisa Waiyaput; Kanthanadon Dittharot; Tharintorn Chansoon; Artit Jinawath; Yada Tingthanatikul
Journal:  Int J Fertil Steril       Date:  2022-05-08

8.  Inhibition of erythropoietin-producing hepatoma receptor B4 (EphB4) signalling suppresses the vascularisation and growth of endometriotic lesions.

Authors:  Jeannette Rudzitis-Auth; Sophia A Fuß; Vivien Becker; Michael D Menger; Matthias W Laschke
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

Review 9.  PPARγ Agonists: Emergent Therapy in Endometriosis.

Authors:  Alexandre Vallée; Jean-Noël Vallée; Alain Le Blanche; Yves Lecarpentier
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-06

10.  M1 Macrophage-Derived Nanovesicles Repolarize M2 Macrophages for Inhibiting the Development of Endometriosis.

Authors:  Qiuju Li; Ming Yuan; Xue Jiao; Yufei Huang; Jing Li; Dong Li; Miaomiao Ji; Guoyun Wang
Journal:  Front Immunol       Date:  2021-07-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.